Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab.
Publication/Presentation Date
10-1-2013
Abstract
RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NSCLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NSCLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NSCLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.
Volume
14
Issue
10
First Page
883
Last Page
887
ISSN
1555-8576
Published In/Presented At
Zaorsky, N. G., Sun, Y., Wang, Z., Palmer, J., Fortina, P. M., Solomides, C., Werner-Wasik, M., Dicker, A. P., Axelrod, R., Campling, B., Evans, N., 3rd, Cowan, S., & Lu, B. (2013). Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. Cancer biology & therapy, 14(10), 883–887. https://doi.org/10.4161/cbt.25942
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
23917487
Department(s)
Administration and Leadership
Document Type
Article